HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on ASLAN Pharmaceuticals (NASDAQ:ASLN) and maintained a $9 price target on the stock.
May 03, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ASLAN Pharmaceuticals (NASDAQ:ASLN) receives a reiterated Buy rating and a maintained $9 price target from HC Wainwright & Co.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards ASLAN Pharmaceuticals. This endorsement may lead to increased investor confidence in ASLN's stock, potentially driving up its price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100